IMMUNOGEN INC Contracts & Agreements

Agreement and Plan of Merger, dated as of November 30, 2023, among the Company, Parent, Intermediate Sub and Purchaser (Filed With SEC on November 30, 2023)

Change in Control Severance Agreement dated as of September18, 2023 between the Registrant and Lauren White (Filed With SEC on November 2, 2023)

Offer Letter dated as of September 18, 2023 between the Registrant and Lauren White (Filed With SEC on November 2, 2023)

Compensation Policy for Non-Employee Directors, as amended through June 14, 2023 (Filed With SEC on July 31, 2023)

Underwriting Agreement dated May 4, 2023 by and among ImmunoGen, Inc. and Jefferies LLC, Goldman Sachs & Co. LLC and Guggenheim Securities, LLC, as representatives of the several... (Filed With SEC on May 5, 2023)

Exchange Agreement, dated May 1, 2023, by and among ImmunoGen, Inc. and RA Capital Healthcare Fund, L.P (Filed With SEC on May 2, 2023)

License and Option Agreement dated as of February 28, 2023 by and between ImmunoGen, Inc. and Vertex Pharmaceuticals Incorporated (Filed With SEC on April 28, 2023)

Description of Securities (Filed With SEC on March 1, 2023)

Form of Restricted Stock Unit Agreement under the 2018 Plan, as amended February 3, 2023 (Filed With SEC on March 1, 2023)

Form of Non-Qualified Stock Option Agreement for Non-Employee Directors, as amended December 15, 2022 (Filed With SEC on March 1, 2023)

Form of Restricted Stock Unit Agreement for Non-Employee Directors as of December 15, 2022 (Filed With SEC on March 1, 2023)

2004 Non-Employee Director Compensation and Deferred Stock Unit Plan, as amended and restated on December 15, 2022 (Filed With SEC on March 1, 2023)

Change in Control Severance Agreement dated as of January 5, 2021 between the Registrant and Renee Lentini (Filed With SEC on March 1, 2023)

Change in Control Severance Agreement dated as of December 29, 2022 between the Registrant and Michael J. Vasconcelles (Filed With SEC on March 1, 2023)

Offer Letter dated as of December 29, 2022 between the Registrant and Michael J. Vasconcelles (Filed With SEC on March 1, 2023)

First Amendment to Offer Letter dated as of December 29, 2022 between the Registrant and Michael J. Vasconcelles (Filed With SEC on March 1, 2023)

Compensation Policy for Non-Employee Directors, as amended through December 15, 2022 (Filed With SEC on March 1, 2023)

Inducement Equity Incentive Plan, as amended December 15, 2022 (Filed With SEC on March 1, 2023)

Form of Restricted Stock Unit Agreement (Inducement Plan), as amended February 3, 2023 (Filed With SEC on March 1, 2023)

Inducement Equity Incentive Plan, as amended (Filed With SEC on August 1, 2022)

Amended and Restated 2018 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on June 17, 2022)

License Agreement dated as of February 14, 2022 by and between the Registrant and Eli Lilly and Company (Filed With SEC on May 6, 2022)

First Amendment to Agreements dated as of December 9, 2013 by and between the Registrant and Eli Lilly and Company (Filed With SEC on February 28, 2022)

Development and License Agreement with Biogen Idec., Inc. dated October 1, 2006 (Filed With SEC on February 28, 2022)

Change in Control Severance Agreement dated November 15, 2021 between the Registrant and Kristen Harrington-Smith (Filed With SEC on February 28, 2022)

Compensation Policy for Non-Employee Directors, as amended through December 16, 2021 (Filed With SEC on February 28, 2022)

Underwriting Agreement dated December 1, 2021 by and among ImmunoGen, Inc. and Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters named in... (Filed With SEC on December 3, 2021)

Form of Pre-Funded Warrant (Filed With SEC on December 3, 2021)

Form of Pre-Funded Warrant (Filed With SEC on August 12, 2021)

Securities Purchase Agreement dated August 11, 2021 between ImmunoGen, Inc. and RA Capital Healthcare Fund, L.P (Filed With SEC on August 12, 2021)

Amended and Restated 2018 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on June 17, 2021)

Compensation Policy for Non-Employee Directors, as amended through June 16, 2021 (Filed With SEC on June 17, 2021)

Inducement Equity Incentive Plan, as amended (Filed With SEC on May 10, 2021)

Description of Securities (Filed With SEC on March 1, 2021)

Collaboration and License Agreement effective as of October 19, 2020 by and between the registrant and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a subsidiary of Huadong... (Filed With SEC on March 1, 2021)

Change in Control Severance Agreement dated as of June 1, 2020 between the Registrant and Stacy Coen (Filed With SEC on March 1, 2021)

Open Market Sale AgreementSM, dated December 18, 2020, by and between ImmunoGen, Inc. and Jefferies LLC (Filed With SEC on December 18, 2020)

Open Market Sale AgreementSM, dated September 25, 2020, by and between ImmunoGen, Inc. and Jefferies LLC (Filed With SEC on September 25, 2020)

Form of Performance-Based Stock Option Agreement (February 2020) under the Inducement Equity Incentive Plan (Filed With SEC on August 5, 2020)

Employment Offer Letter dated June 30, 2020 between the Registrant and Susan Altschuller (Filed With SEC on August 5, 2020)

Change in Control Severance Agreement dated as of July 20, 2020 between the Registrant and Susan Altschuller, Ph.D (Filed With SEC on August 5, 2020)

Inducement Equity Incentive Plan - as amended (Filed With SEC on July 2, 2020)

Compensation Policy for Non-Employee Directors, as amended through June 17, 2020 (Filed With SEC on June 18, 2020)

Inducement Equity Incentive Plan as amended (Filed With SEC on May 5, 2020)

Description of Securities (Filed With SEC on March 11, 2020)

First Amendment to Collaboration and Option Agreement dated as of November 20, 2019 by and between the Registrant and Jazz Pharmaceuticals Ireland Limited (Filed With SEC on March 11, 2020)

Form of Performance-Based Stock Option Agreement dated February 7, 2020 (Filed With SEC on March 11, 2020)

Underwriting Agreement dated January 22, 2020 by and among ImmunoGen, Inc. and Jefferies LLC, Cowen and Company, LLC and William Blair & Company, L.L.C., as representatives of the... (Filed With SEC on January 23, 2020)

Inducement Equity Incentive Plan (Filed With SEC on December 20, 2019)

Form of Stock Option Agreement under the Inducement Equity Incentive Plan (Filed With SEC on December 20, 2019)

Form of Restricted Stock Unit Agreement under the Inducement Equity Incentive Plan (Filed With SEC on December 20, 2019)

Employee Stock Purchase Plan, as amended through September 27, 2019 (Filed With SEC on November 5, 2019)

Severance Pay Plan for Vice Presidents and Higher, as amended through June 20, 2019 (Filed With SEC on August 7, 2019)

Form of Performance-Based Restricted Stock Agreement dated April 3, 2019 (Filed With SEC on May 7, 2019)

Eleventh Amendment to Lease dated as of February 27, 2019 by and between Bobson Norwood Commercial, LLC and the Registrant (Filed With SEC on March 1, 2019)

Royalty Purchase Agreement dated as of January 8, 2019 among the Registrant, Hurricane, LLC, Immunity Royalty Holdings, L.P., and OMERS IP Healthcare Holdings Limited (Filed With SEC on March 1, 2019)

Tenth Amendment to Lease dated as of June 27, 2018 by and between Bobson Norwood Commercial, LLC, lessor, and the Registrant (Filed With SEC on August 3, 2018)

2018 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on June 22, 2018)

Form of Incentive Stock Option Agreement under the 2018 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on June 22, 2018)

Form of Non-Qualified Stock Option Agreement for employees under the 2018 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on June 22, 2018)

Form of Restricted Stock Unit Agreement under the 2018 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on June 22, 2018)

Form of Non-Qualified Stock Option Agreement for Non-Employee Directors under the 2018 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on June 22, 2018)

Form of Deferred Stock Unit Agreement for Non-Employee Directors under the 2018 Employee, Director and Consultant Equity Incentive Plan (Filed With SEC on June 22, 2018)

Employee Stock Purchase Plan (Filed With SEC on June 22, 2018)

Underwriting Agreement dated June 6, 2018 by and among ImmunoGen, Inc. and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Cowen and Company LLC, as representatives of the... (Filed With SEC on June 7, 2018)

Compensation Policy for Non-Employee Directors, as amended through March 28, 2018 (Filed With SEC on May 9, 2018)

Fourth Amendment to Lease Agreement dated as of April 6, 2018 by and between CRP/King 830 Winter L.L.C., landlord, and the Registrant (Filed With SEC on May 9, 2018)

Development and License Agreement, dated as of October 20, 2008, by and between the Company and Bayer HealthCare AG (Filed With SEC on May 9, 2018)

Multi-Target Agreement, dated as of December 19, 2011, by and between the Company and Eli Lilly (Filed With SEC on May 9, 2018)

Change in Control Severance Agreement dated April 23, 2018 between the Registrant and Blaine H. McKee (Filed With SEC on May 9, 2018)

Severance Pay Plan for Vice Presidents and Higher, as amended through February 15, 2018 (Filed With SEC on March 7, 2018)

Summary of ImmunoGen Incentive Bonus Plan (Filed With SEC on February 20, 2018)

Underwriting Agreement dated October 5, 2017 by and among ImmunoGen, Inc. and Jefferies LLC, Leerink Partners LLC, RBC Capital Markets, LLC, as representatives of the several... (Filed With SEC on October 6, 2017)

Form of Exchange Agreement (Filed With SEC on September 26, 2017)

Form of Exchange Agreement (Filed With SEC on September 1, 2017)

EXCLUSIVE LICENSE AND ASSET PURCHASE AGREEMENT (Filed With SEC on August 4, 2017)

AMENDMENT NO. 4 TO THE Collaboration and License Agreement (Filed With SEC on August 4, 2017)

RESTRICTED STOCK AGREEMENT IMMUNOGEN, INC. (Filed With SEC on August 4, 2017)

PERFORMANCE BASED RESTRICTED STOCK AGREEMENT IMMUNOGEN, INC. (Filed With SEC on August 4, 2017)

IMMUNOGEN, INC. 2016 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN (as amended June 13, 2017) (Filed With SEC on June 16, 2017)

CHANGE IN CONTROL SEVERANCE AGREEMENT (Filed With SEC on May 5, 2017)

Options Granted (Filed With SEC on December 13, 2016)

DEFERRED STOCK UNIT AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE IMMUNOGEN, INC. 2016 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN AND THE COMPENSATION POLICY FOR... (Filed With SEC on December 13, 2016)

IMMUNOGEN, INC. 2016 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN (Filed With SEC on December 13, 2016)

Options Granted (Filed With SEC on December 13, 2016)

IMMUNOGEN INC. SEVERANCE PAY PLAN AND SUMMARY PLAN DESCRIPTION FOR VICE PRESIDENTS AND HIGHER As amended through September 23, 2016 (Filed With SEC on September 29, 2016)

CHANGE IN CONTROL SEVERANCE AGREEMENT (Filed With SEC on August 25, 2016)

PERFORMANCE BASED RESTRICTED STOCK AGREEMENT IMMUNOGEN, INC. (Filed With SEC on August 17, 2016)

ImmunoGen, Inc. (Company) Wilmington Trust, National Association (Trustee) 4.50% Convertible Senior Notes due 2021 INDENTURE Dated as of June 20, 2016 (Filed With SEC on June 20, 2016)

J.P. MORGAN SECURITIES LLC PURCHASE AGREEMENT IMMUNOGEN, INC. 4.50% Convertible Senior Notes due 2021 Purchase Agreement (Filed With SEC on June 20, 2016)

IMMUNOGEN, INC. AMENDMENT TO STOCK OPTION AGREEMENTS (Filed With SEC on May 4, 2016)

Options Exercised (Filed With SEC on April 26, 2016)

830 Winter Street Waltham, Massachusetts 02451 (the Building) THIRD AMENDMENT (Filed With SEC on February 4, 2016)

CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on February 5, 2015)

CHANGE IN CONTROL SEVERANCE AGREEMENT (Filed With SEC on February 5, 2015)

IMMUNOGEN, INC. 2006 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN (as amended and restated through November 11, 2014) (Filed With SEC on November 13, 2014)

SUMMARY OF ANNUAL BONUS PROGRAM (Filed With SEC on November 13, 2014)

[ImmunoGen Letterhead] (Filed With SEC on October 30, 2014)

CHANGE IN CONTROL SEVERANCE AGREEMENT (Filed With SEC on October 30, 2014)

SUMMARY OF ANNUAL BONUS PROGRAM (Filed With SEC on October 30, 2014)

AMENDMENT NO. 1 TO THE COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on October 30, 2014)

AMENDMENT NO. 2 TO THE COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on October 30, 2014)

AMENDMENT NO. 3 TO THE COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on October 30, 2014)

IMMUNOGEN INC. SEVERANCE PAY PLAN AND SUMMARY PLAN DESCRIPTION FOR VICE PRESIDENTS AND HIGHER Effective as of September 17, 2014 (Filed With SEC on September 18, 2014)

SUMMARY OF ANNUAL BONUS PROGRAM (Filed With SEC on June 16, 2014)

SECOND AMENDMENT TO LEASE AGREEMENT (Filed With SEC on May 2, 2014)

CHANGE IN CONTROL SEVERANCE AGREEMENT (Filed With SEC on May 2, 2014)

FIRST AMENDMENT TO LEASE AGREEMENT (Filed With SEC on February 5, 2014)

CONFIDENTIAL TREATMENT REQUESTED FIRST AMENDMENT TO AGREEMENTS (Filed With SEC on February 5, 2014)

ImmunoGen, Inc. Compensation Policy for Non-Employee Directors (Filed With SEC on February 5, 2014)

EMPLOYMENT AGREEMENT (Filed With SEC on February 5, 2014)

CHANGE IN CONTROL SEVERANCE AGREEMENT (Filed With SEC on February 5, 2014)

TRANSITION AND SEPARATION AGREEMENT (Filed With SEC on October 29, 2013)

FIRST AMENDMENT TO MULTI-TARGET AGREEMENT (Filed With SEC on May 6, 2013)

CHANGE IN CONTROL SEVERANCE AGREEMENT (Filed With SEC on January 30, 2013)

EMPLOYMENT AGREEMENT (Filed With SEC on January 30, 2013)

THIRD AMENDMENT TO LICENSE AGREEMENT FOR ANTI-HER2 ANTIBODIES (Filed With SEC on January 30, 2013)

IMMUNOGEN, INC. 2006 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN (as amended and restated through November 13, 2012) (Filed With SEC on November 16, 2012)

IMMUNOGEN, INC. 2006 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN (as amended June 13, 2012(1)) (Filed With SEC on August 29, 2012)

Options Exercised (Filed With SEC on August 29, 2012)

ImmunoGen, Inc. 6,250,000 Shares of Common Stock, par value $0.01 per share Underwriting Agreement (Filed With SEC on July 12, 2012)

DEVELOPMENT AND LICENSE AGREEMENT (Filed With SEC on May 10, 2012)

MULTI-TARGET AGREEMENT (Filed With SEC on May 10, 2012)

LICENSE AGREEMENT (Filed With SEC on October 31, 2011)

OPTION AND LICENSE AGREEMENT (Filed With SEC on October 31, 2011)

ImmunoGen, Inc. 7,000,000 Shares of Common Stock, par value $0.01 per share Underwriting Agreement (Filed With SEC on May 20, 2011)

CLINICAL SUPPLY AGREEMENT (Filed With SEC on February 8, 2011)

SEVERANCE AGREEMENT (Filed With SEC on February 8, 2011)

NINTH AMENDMENT OF LEASE (Filed With SEC on November 18, 2010)

IMMUNOGEN, INC. 2006 EMPLOYEE, DIRECTOR ANDCONSULTANT EQUITY INCENTIVE PLAN (as amended and restated through November 16, 2010) (Filed With SEC on November 18, 2010)

ImmunoGen, Inc. Compensation Policy for Non-Employee Directors (Filed With SEC on October 29, 2010)

ImmunoGen, Inc. 9,000,000 Shares of Common Stock, par value $0.01 per share UnderwritingAgreement (Filed With SEC on May 7, 2010)

ImmunoGen, Inc. Compensation Policy forNon-Employee Directors (Filed With SEC on January 29, 2010)

SEVERANCE AGREEMENT (Filed With SEC on January 29, 2010)

IMMUNOGEN, INC. 2004NON-EMPLOYEE DIRECTOR COMPENSATION ANDDEFERRED SHARE UNIT PLAN (asamended through September 16, 2009) (Filed With SEC on November 4, 2009)

ImmunoGen, Inc. Compensation Policy for Non-Employee Directors (Filed With SEC on November 4, 2009)

SEVERANCE AGREEMENT (Filed With SEC on August 28, 2009)

5,000,000 Shares ImmunoGen, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on June 18, 2009)

AMENDMENT TO LICENSE AGREEMENTS (Filed With SEC on May 7, 2009)

SEVERANCE AGREEMENT (Filed With SEC on February 6, 2009)

AMENDMENT NO. 3 TO THE COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on February 6, 2009)

IMMUNOGEN, INC. 2006 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITYINCENTIVE PLAN (as amended and restated through November 12, 2008) (Filed With SEC on November 14, 2008)

IMMUNOGEN, INC. AMENDMENT TO STOCK OPTION AGREEMENTS (Filed With SEC on October 31, 2008)

THIRD AMENDMENT AND PARTIAL TERMINATION OF LEASE (Filed With SEC on September 2, 2008)

FOURTH AMENDMENT OF LEASE (Filed With SEC on September 2, 2008)

FIFTH AMENDMENT OF LEASE (Filed With SEC on September 2, 2008)

SIXTH AMENDMENT OF LEASE Bobson 333 LLC to ImmunoGen, Inc. (Filed With SEC on September 2, 2008)

SEVENTH AMENDMENT OF LEASE Bobson 333 LLC to ImmunoGen, Inc. (Filed With SEC on September 2, 2008)

EIGHTH AMENDMENT OF LEASE (Filed With SEC on September 2, 2008)

AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on September 2, 2008)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on June 23, 2008)

EMPLOYMENT AGREEMENT (Filed With SEC on February 7, 2008)

SEVERANCEAGREEMENT (Filed With SEC on February 7, 2008)

PROPRIETARYINFORMATION, INVENTIONS, AND COMPETITION AGREEMENT (Filed With SEC on February 7, 2008)

AMENDMENT NO. 2 TO THE COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on February 7, 2008)

SUMMARY OF ANNUAL EXECUTIVE BONUS PROGRAM (Filed With SEC on November 7, 2007)

LEASE AGREEMENT by and between INTERCONTINENTALFUND III 830 WINTER STREET, LLC, as Landlord and IMMUNOGEN, INC., as Tenant With respect tothe property known as 830 Winter Street,... (Filed With SEC on November 7, 2007)

SCALE UP AGREEMENT (Filed With SEC on August 30, 2007)

LICENSE AGREEMENT (Filed With SEC on May 9, 2007)

PROCESS DEVELOPMENT AGREEMENT (Filed With SEC on August 28, 2006)

Amendment to License Agreement for Anti-HER2 Antibodies (Filed With SEC on August 28, 2006)

IMMUNOGEN, INC. RESTATED STOCK OPTION PLAN (as amended through February 1, 2006) (Filed With SEC on February 7, 2006)

INCENTIVE STOCK OPTION AGREEMENT IMMUNOGEN, INC. (Filed With SEC on February 7, 2006)

NON-QUALIFIED STOCK OPTION AGREEMENT IMMUNOGEN, INC. (Filed With SEC on February 7, 2006)

ImmunoGen, Inc. (Filed With SEC on June 16, 2005)

TERMINATION OF THEDEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT MADE BETWEEN VERNALIS(R&D) LIMITED (Filed With SEC on May 14, 2004)

Development and License Agreement (Filed With SEC on February 14, 2002)

Category

Industry

Companies

Contracts

IMMUNOGEN INC Contracts & Agreements